Three primary strategies proposed to overcome resistance are combining with synergistic anti-tumor drugs, novel therapeutics to targeting acquired resistance-related deficiencies and suppressing mutant phenotypes (mechanisms of PARP inhibition resistance and strategies to overcome are summarized in Fig. 6). Here, PARP1 is linked to neoplasm.